LOLA (l-ornithine-l-aspartate) is not frequently used as there are still some reservations about its benefits. This study assesses the effectiveness and safety of LOLA in the management of hepatic ...

The pharmacokinetic profile of ARCT-810 was favorable, and preliminary data shows that no ARCT-810 lipid was detectable in the plasma beyond 48 hours following drug administration.

LUNAR® lipids undetectable in plasma 48 hours following drug administration. ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 ...

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver ...